PERFUSION, vol.16, no.9, pp.318-323, 2003 (SCI-Expanded)
Background: Cardiac surgery involving cardiopulmonary bypass is associated with reperfusion injury and an inflammatory process. In a previous study, we showed the potential myocardial protective effects of trimetazidine pretreatment by measuring the cardiac marker protein troponin T (TnT) during coronary bypass operations. However, it is not known whether trimetazidine has a preventive effect on the cardiopulmonary bypass-induced inflammation. The aim of the present study was to investigate whether pretreatment with trimetazidine, a cellular anti-ischemic agent can prevent the deleterious effects of cardiopulmonary bypass-induced inflammation.